Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for GreenScreen HC
3 Mar 2009Product News
Gentronix Limited [Manchester, UK] announced today that it has entered into an agreement to provide GlaxoSmithKline (GSK) with its novel genotoxicity detection assay GreenScreen HC.
GreenScreen HC is the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay is amenable to high throughput screening, provides additional data for safety profiling, consumes very low quantities of compound and gives rapid results.
The proprietary reporter based assay detects all known classes of genotoxic agent and utilizes Green Fluorescent Protein in order to detect GADD-45a up-regulation which is a key indicator of DNA damage.
John Nicholson, CEO and Chairman of Gentronix said ‘we have worked with GSK previously on the early validation of our technology and are delighted that they will be incorporating GreenScreen HC into their safety evaluation activities. This agreement provides important validation of our technology and demonstrates the value we bring to our customers’.
Related Products
Request Quote for All Products
GreenScreen HC
Gentronix Ltd.Gentronix has launched a new, accurate and fast in vitro mammalian cell genotoxicity assay - GreenScreen HC. The TK6 host cells are p53 competent and familiar to most genetic toxicology laboratories. A patented GFP reporter system exploits the proper regulation of the GADD45a gene. The assay delivers both high specificity and high sensitivity and detects all common mechanistic classes of genotoxin. The 96-well microplate format takes about 20 minutes to prepare and delivers results after a 48 hour incubation. A single microplate is sufficient for the simultaneous testing of 4 compounds over 9 serial dilutions. The protocol is also readily automated using standard laboratory liquid-handling equipment. The Biology GADD45a mediates the adaptive response to genotoxic stress. The patented GFP fluorescence reporter includes complex regulatory elements. The assay gives positive results for direct acting agents, as well as aneugens, and topoisomerase and polymerase inhibitors. Importantly the assay gives correct negative results for non-carcinogens, including many which give misleading positive results in other in vitro tests. The Assay Protocol Nine, 2-fold dilutions of each compound together with positive controls are set out in the microplate and growing cells are added to each well. After incubation and measurement in a microplate reader, simple software gives automated decisions and a clear graphical output. Validation A unique combination of both high-specificity and high-sensitivity genotoxicity assessment in a human cell line has been demonstrated. See: High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Hastwell P.W. et al (2006) Mutation Research 607: 160-175.